论文部分内容阅读
Objective:The association between ribonuclease L(RNASEL)gene polymorphisms and prostate cancer risk has been widely reported,but the results of these studies remained controversial and underpowered.We performed a meta-analysis of 28 studies to evaluate the association between Arg462Gln and Asp541Glu polymorphisms in the RNASEL gene and prostate cancer risk.Methods:Odds ratios(ORs)with 95%confidence intervals(CIs) were estimated to assess the association between RNASEL polymorphisms and prostate cancer risk.Results:A significantly increased prostate cancer risk was found for the Arg462Gln polymorphism in Africans(Gln/Gln vs Arg/Arg:OR=2.50,95%CI=1.28-4.87;Gln/Gln vs Gln/Arg+Arg/Arg:OR=2.54,95%CI=1.30-4.95),but not in Europeans and Asians.Additionally,the Asp541Glu polymorphism was associated with increased total prostate cancer risk(Glu-allele vs Asp-allele:OR=1.04,95%CI=1.01-1.07;Glu/Glu vs Asp/Asp:OR=1.22,95%CI= 1.03-1.46;Glu/Glu vs Glu/Asp+Asp/Asp:OR=1.09,95%CI=1.02-1.16).In the stratified analysis for the Asp541Glu polymorphism,there was a significantly increased prostate cancer risk in Africans and Europeans,and in hospital-based prostate cancer cases.Conclusion:The meta-analysis results showed evidence that RNASEL Arg462Gln and Asp541Glu polymorphisms are associated with prostate cancer risk and could be low-penetrance prostate cancer susceptibility biomarkers.
Objective: The association between ribonuclease L (RNASEL) gene polymorphisms and prostate cancer risk has been widely reported, but the results of these studies remained controversial and underpowered. We performed a meta-analysis of 28 studies to evaluate the association between Arg462Gln and Asp541Glu polymorphisms in the RNASEL gene and prostate cancer risk. Methods: Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between RNASEL polymorphisms and prostate cancer risk. Results: A significant increased prostate cancer risk was found for the Arg462 Gln polymorphism in Africans (Gln / Gln vs Arg / Arg: OR = 2.50, 95% CI = 1.28-4.87; Gln / Gln vs Gln / Arg + Arg / Arg: OR = 2.54, 95% CI = 1.30-4.95) but not in Europeans and Asians.Additionally, the Asp541Glu polymorphism was associated with increased total prostate cancer risk (Glu-allele vs Asp-allele: OR = 1.04, 95% CI = 1.01-1.07; Glu / Glu vs Asp / Asp: OR = 1.22, 95% CI = 1.03-1.46; Glu / Glu vs Glu / Asp + Asp / Asp: OR = 1.09, 95% CI = 1.02-1.16) tified analysis for the Asp541Glu polymorphism, there was a significant increased prostate cancer risk in Africans and Europeans, and in hospital-based prostate cancer cases. Confluence: The meta-analysis results showing evidence evidence that RNASEL Arg462Gln and Asp541Glu polymorphisms are associated with prostate cancer risk and could be low-penetrance prostate cancer susceptibility biomarkers.